Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report  
Delayed Quote. Delayed Nyse - 06/19 04:00:53 pm
115.23 USD   +0.51%
06/19ELI LILLY AND : How the Rebate Wall Limits Competition, Access
PU
06/19ELI LILLY AND : Lilly Declares Third-Quarter 2019 Dividend
PR
06/15Drug Firms Sue Over Ad Rule -- WSJ
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/13/2019 06/14/2019 06/17/2019 06/18/2019 06/19/2019 Date
111.82(c) 111.74(c) 113.4(c) 114.65(c) 115.23(c) Last
8 477 341 3 188 051 3 032 339 2 868 693 3 320 718 Volume
-2.97% -0.07% +1.49% +1.10% +0.51% Change
More quotes
Financials (USD)
Sales 2019 22 208 M
EBIT 2019 6 232 M
Net income 2019 6 972 M
Debt 2019 7 773 M
Yield 2019 2,10%
Sales 2020 23 650 M
EBIT 2020 7 203 M
Net income 2020 5 554 M
Debt 2020 5 867 M
Yield 2020 2,24%
P/E ratio 2019 13,62
P/E ratio 2020 19,39
EV / Sales2019 5,52x
EV / Sales2020 5,11x
Capitalization 115 B
More Financials
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (17.4%); - veterinary medicine (12.8%); - cardiovascular... 
Sector
Pharmaceuticals
Calendar
07/30 | 06:25amEarnings Release
More about the company
Surperformance© ratings of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on ELI LILLY AND COMPANY
06/19ELI LILLY AND : How the Rebate Wall Limits Competition, Access
PU
06/19ELI LILLY AND : Lilly Declares Third-Quarter 2019 Dividend
PR
06/15Drug Firms Sue Over Ad Rule -- WSJ
DJ
06/14Drugmakers Sue to Block Federal Rule Requiring Drug Prices in TV Ads
DJ
06/14ELI LILLY AND : Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humi..
PU
06/12ELI LILLY AND : Detailed findings from CAROLINA outcome trial support long-term ..
AQ
06/11ELI LILLY AND : Boehringer Ingelheim and Eli Lilly and Company - Detailed findin..
AQ
06/11ELI LILLY AND : Boehringer Ingelheim Pharmaceuticals, Inc. - New analysis shows ..
AQ
06/11EPISODIC CLUSTER HEADACHE : A Pressing Need That Must Be Addressed
PU
06/11ELI LILLY AND : Lilly to Present 5-Year Sustained Efficacy and Safety Results fo..
PU
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Sector news : Pharmaceuticals - NEC
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GLAXOSMITHKLINE : GSK kicks off sale of $1.2 billion consumer health drugs - sou..
RE
06/19CEOs of some U.S. firms to meet Chinese Premier Li this week - Bloomberg
RE
06/19SANOFI : plans 466 job cuts as part of R&D reshuffle
RE
06/19GLOBAL MARKETS LIVE : Viacom, Apple, Siemens, Boeing…
More sector news : Pharmaceuticals - NEC
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 125 $
Spread / Average Target 5,7%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Michael R. Meadows VP & Chief Technology Officer
Aarti Shah Chief Information Officer & SVP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY-0.92%113 364
JOHNSON & JOHNSON8.66%348 981
PFIZER-1.33%233 072
ROCHE HOLDING LTD.14.63%227 848
NOVARTIS22.44%220 893
MERCK AND COMPANY10.57%206 641